Protara Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protara Therapeutics, Inc. (TARA) on September 23, 2020, covering events occurring on September 21 and September 22, 2020. The filing details the entry into material definitive agreements for a concurrent public offering of common and preferred stock.
Key Financial Metrics and Transaction Details
The Company entered into underwriting agreements for two separate, concurrent offerings expected to generate gross proceeds of approximately $147.6 million before deducting underwriting discounts, commissions, and estimated offering expenses.
- Common Stock Offering: 4,600,000 shares at an offering price of $16.87 per share.
- Preferred Stock Offering: 4,148 shares of Non-Voting Series 1 Convertible Preferred Stock at an offering price of $16,873.54 per share.
- Underwriters: Cowen and Company, LLC and Guggenheim Securities, LLC.
- Expected Closing: On or about September 24, 2020, subject to customary closing conditions.
The filing does not provide specific historical revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes and Corporate Actions
In connection with the Preferred Offering, the Company filed a Certificate of Amendment with the Delaware Secretary of State to increase the authorized number of Series 1 Convertible Preferred Stock shares from 3,880 to 8,028. This amendment was approved by a board committee and requisite preferred stockholders; common stockholder approval was not required.
Additionally, the Company and its directors and executive officers have agreed to a 90-day lock-up period, prohibiting the sale or transfer of Common Stock without the written consent of Cowen and Company, LLC, effective from September 22, 2020.
Outlook, Risks, and Contingencies
The completion, timing, and size of the Offerings are subject to customary closing conditions. The filing includes forward-looking statements regarding expected proceeds and closing dates, which are subject to risks and uncertainties, including market conditions. Actual results may differ materially from expectations. Further risk factors are referenced in the Company's Form 10-Q for the quarter ended June 30, 2020.
Key Facts for Investor Verification
- Verify the final closing date and actual gross proceeds received after deducting underwriting discounts and expenses.
- Confirm the conversion terms and rights of the newly issued Series 1 Convertible Preferred Stock.
- Review the use of proceeds disclosed in the related prospectus supplements to understand capital allocation plans.
- Monitor the 90-day lock-up expiration date for potential share sales by insiders.